|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.85 SEK | -0.71% |
|
+0.72% | -46.44% |
| Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
| Feb. 15 | Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Genovis AB (publ.) reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 27.31 million compared to SEK 25.74 million a year ago. Revenue was SEK 29.03 million compared to SEK 26 million a year ago.
Net loss was SEK 0.422 million compared to SEK 7.51 million a year ago. Basic loss per share from continuing operations was SEK 0.01 compared to SEK 0.11 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -46.44% | 168M | |
| +1.09% | 12.95B | |
| -7.57% | 7.84B | |
| +2.02% | 5.5B | |
| +0.02% | 4.61B | |
| +7.73% | 4.61B | |
| -48.21% | 3.4B | |
| +9.21% | 2.66B | |
| -14.59% | 2.08B | |
| +2.51% | 1.79B |
GENOVIS AB 
